Mike Brem is an accomplished cell biologist and protein scientist with over 23 years of industry experience in the biologics arena centered on therapeutic protein production, host cell engineering, and stable cell line development in both small and large pharma environments. One of Mike’s most impactful projects was the generation of the stable cell lines for Myozyme® and Lumizyme® approved by the FDA for the treatment of Pompe disease (Sanofi Genzyme). His current responsibilities are focused on the build out of Wheeler’s cell line development laboratories and platform manufacturing technology (ECHO2™), and he leads the integration of ECHO2™ in the Wheeler East location in Waltham, MA. Mike holds a bachelor’s degree in biology from East Central University.